The top five most common TEAEs were WBC decreased (41%), anemia (38%), rash or acne (37%), PLT decreased (28%), and diarrhea (24%) in the FLAURA China study [23], while that in this phase IIa study of rezivertinib were WBC decreased (44.2%), PLT decreased (41.9%), ANC decreased (32.6%), anemia (30.2%), and ALT increased (20.9%). This evidence concerns the gene GPT and anemia (phenotype).